Braingrade, founded by a team of experienced executives and founders from leading neurotech companies, aims to revolutionize Alzheimer's care through advanced neurostimulation technology. The company's core mission is to enhance human cognition and extend the healthy lifespan of Alzheimer's patients by up to ten years, far surpassing the capabilities of current medications. Braingrade's primary product is an intelligent brain implant (DBS/BCI) designed to preserve brain health and improve the quality of life for those affected by Alzheimer's disease.
Notable figures affiliated with Braingrade include top memory enhancement researchers, neurosurgeons, and neurologists who contribute to the development of their innovative solutions. The company has garnered attention for its potential to significantly impact Alzheimer's treatment, positioning itself as a leader in the neurotech industry. Braingrade's achievements include pioneering advancements in brain-computer interface technology and setting new benchmarks for patient care in neurodegenerative diseases.
